Notable Pharmaceutical Companies – Novo Nordisk and AstraZeneca, To Receive the Outstanding Corporate Partner Award

Friday, April 29, 2016 2:44 pm EDT

Dateline:

Jacksonville, Fla.
"We look forward to continuing our work as a Corporate Partner and partnering with AACE to bring meaningful advancements in the field of endocrinology and most importantly improve the lives of patients."

The American Association of Clinical Endocrinologists (AACE) named Novo Nordisk and AstraZeneca as the 2016 winners of the Outstanding Corporate Partner Award, which are scheduled to be presented prior to the opening of the 25th Annual American Association of Clinical Endocrinologists’ (AACE) Scientific & Clinical Congress, slated on May 25-29 in Orlando, Florida. 

The AACE Outstanding Corporate Partner Award is presented to an industry partner(s) who is a member of the Corporate AACE Partnership (CAP) and has demonstrated outstanding commitment and dedication as a partner with AACE to improve the health of patients through various programs and initiatives promoting the future of endocrinology.

“We are proud to be named Outstanding Corporate Partner by AACE leadership. At Novo Nordisk, our aim is to defeat diabetes and other serious chronic conditions,” said Todd Hobbs, MD, Chief Medical Officer for Novo Nordisk North America. “We look forward to continuing our work as a Corporate Partner and partnering with AACE to bring meaningful advancements in the field of endocrinology and most importantly improve the lives of patients.”

“AstraZeneca is humbled and most pleased to accept this award,” said Jim McDermott, Executive Director, U.S. Diabetes, AstraZeneca. “As an organization committed to a patient-centric approach to disease management, we are not afraid to push the boundaries of science to deliver life-changing medicines.  We consider our partnership with AACE as valuable input to accomplish that goal.”

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given Novo Nordisk the experience and capabilities that also enable them to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone-related disorders, and obesity. 

Headquartered in London, United Kingdom, AstraZeneca is a global, science-led, bio-pharmaceutical company.  

###

About the American Association of Clinical Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents more than 7,000 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. A majority of AACE members are certified in endocrinology, diabetes and metabolism and concentrate on the treatment of patients with endocrine and metabolic disorders including diabetes, thyroid disorders, osteoporosis, growth hormone deficiency, cholesterol disorders, hypertension and obesity. Visit our site at  www.aace.com.

About the American College of Endocrinology (ACE)

The American College of Endocrinology (ACE) is the educational and scientific arm of the American Association of Clinical Endocrinologists (AACE). ACE is the leader in advancing the care and prevention of endocrine and metabolic disorders by: providing professional education and reliable public health information; recognizing excellence in education, research and service; promoting clinical research and defining the future of Clinical Endocrinology. For more information, please visit  www.aace.com/college. 

Contact:

AACE
Mary Green, 904-353-7878 ext. 163
Asst. Director, Public Relations, Media and Creative
mgreen@aace.com
904-404-4223 (fax)